References
- Smith NK, Hackett TA, Galli A, Flynn CR (2019) GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int 128:94–105. https://doi.org/10.1016/j.neuint.2019.04.010.
- Drucker DJ (2018) Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab 27:740–756. https://doi.org/10.1016/j.cmet.2018.03.001.
- Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46:101102. https://doi.org/10.1016/j.molmet.2020.101102.
- Wong ND, Sattar N (2023) Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol 20:685–695. https://doi.org/10.1038/s41569–023–00877-z.
- Ussher JR, Drucker DJ (2023) Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20:463–474. https://doi.org/10.1038/s41569–023–00849–3.
- Schnell O, Barnard-Kelly K, Battelino T, et al (2024) CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol 23:104. https://doi.org/10.1186/s12933–024–02180–8.
- Teo KK, Rafiq T (2021) Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries. Can J Cardiol 37:733–743. https://doi.org/10.1016/j.cjca.2021.02.009.
- Wang L, Lei J, Wang R, Li K (2023) Non-Traditional Risk Factors as Contributors to Cardiovascular Disease. Rev Cardiovasc Med 24:134. https://doi.org/10.31083/j.rcm2405134.
- SCORE2 working group and ESC Cardiovascular risk collaboration (2021) SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 42:2439–2454. https://doi.org/10.1093/eurheartj/ehab309.
- SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration (2023) SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 44:2544–2556. https://doi.org/10.1093/eurheartj/ehad260.
- Sattar N, Lee MMY, Kristensen SL, et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9:653–662. https://doi.org/10.1016/S2213–8587(21)00203–5.
- Bertoccini L, Baroni MG (2021) GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection. Adv Exp Med Biol 1307:193–212. https://doi.org/10.1007/5584_2020_494.
- Tahrani AA, Morton J (2022) Benefits of weight loss of 10% or more in patients with overweight or obesity: A review. Obesity (Silver Spring) 30:802–840. https://doi.org/10.1002/oby.23371.
- Nauck MA, Quast DR (2021) Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne) 12:645566. https://doi.org/10.3389/fendo.2021.645566.
- Iacobellis G, Ribaudo MC, Assael F, et al (2003) Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 88:5163–8. https://doi.org/10.1210/jc.2003–030698.
- Iacobellis G, Lonn E, Lamy A, et al (2011) Epicardial fat thickness and coronary artery disease correlate independently of obesity. Int J Cardiol 146:452–4. https://doi.org/10.1016/j.ijcard.2010.10.117.
- Iacobellis G, Camarena V, Sant DW, Wang G (2017) Human Epicardial Fat Expresses Glucagon-Like Peptide 1 and 2 Receptors Genes. Horm Metab Res 49:625–630. https://doi.org/10.1055/s-0043–109563.
- Iacobellis G, Baroni MG (2022) Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J Endocrinol Invest 45:489–495. https://doi.org/10.1007/s40618–021–01687–1.
- Schnell O, Battelino T, Bergenstal R, et al (2023) CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol 22:59. https://doi.org/10.1186/s12933–023–01788–6.
- Marso SP, Daniels GH, Brown-Frandsen K, et al (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375:311–22. https://doi.org/10.1056/NEJMoa1603827.
- Pfeffer MA, Claggett B, Diaz R, et al (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 373:2247–57. https://doi.org/10.1056/NEJMoa1509225.
- Marso SP, Bain SC, Consoli A, et al (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375:1834–1844. https://doi.org/10.1056/NEJMoa1607141.
- McGuire DK, Busui RP, Deanfield J, et al (2023) Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab 25:1932–1941. https://doi.org/10.1111/dom.15058.
- Holman RR, Bethel MA, Mentz RJ, et al (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 377:1228–1239. https://doi.org/10.1056/NEJMoa1612917.
- Gerstein HC, Colhoun HM, Dagenais GR, et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130. https://doi.org/10.1016/S0140–6736(19)31149–3.
- Hernandez AF, Green JB, Janmohamed S, et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double--blind, randomised placebo-controlled trial. Lancet 392:1519–1529. https://doi.org/10.1016/S0140–6736(18)32261-X.
- Kristensen SL, Rørth R, Jhund PS, et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776–785. https://doi.org/10.1016/S2213–8587(19)30249–9.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389:2221–2232. https://doi.org/10.1056/NEJMoa2307563.